secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001193125-23-088948
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics amends SVB loan agreement; raises cash collateral requirement eases account covenant
--------------------------------------------------------------------------------

- Third Amendment to Loan & Security Agreement, effective March 30, 2023.
- Cash collateral requirement increased to full outstanding principal plus 5.75% Final Payment, from previous half sum.
- Cash collateral will be reduced proportionally with each scheduled monthly principal and interest payment.
- Operating accounts covenant relaxed: only one account required at SVB instead of all accounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523088948/0001193125-23-088948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523088948/d491593d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-088948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer